What is ALNY's market cap?

Alnylam Pharmaceuticals, Inc. (ALNY) is a listed stock with a live quote. The latest market cap on this page is $30B.

Where is Alnylam Pharmaceuticals, Inc. headquartered?

Alnylam Pharmaceuticals, Inc. is headquartered in Cambridge, MA.

How do I get ALNY news from the API?

Call GET /v1/news?tickers=ALNY. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

How far back does ALNY news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ALNY, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.

Is the ALNY price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

ALNY · NASDAQ

Alnylam Pharmaceuticals, Inc.

$224.03 -2.86 (-1.26%)

Company overview

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1).

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $30B
Employees: 2,230
Headquarters: Cambridge, MA
Website: alnylam.com
CEO: Yvonne L. Greenstreet
Listed: June 1, 2004
P/E: 51.38
Dividend yield: 0.00%

Company financials

Revenue: $4.3B
Gross profit: $3.5B
Operating income: $752M
EBITDA: $614M
Net income: $577M
EPS: $4.36
Total assets: $5.1B
Total debt: $1.3B
Gross margin: 80.89%
Net margin: 13.46%
Earnings yield: 1.95%

Revenue segmentation

By product (FY 2025)

By region (FY 2025)

Showing FY 2025

Price chart

ALNY 1D NASDAQ O224.92H229.82L223.76C227.28+2.18 (+0.97%)Vol2.21M

News

Ticker	Type	Headline	Source	Published
ALNY	Stock news	Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease	Business Wire	Oct 23, 3:45:00 AM ET
ALNY	Stock news	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?	Zacks Investment Research	Oct 22, 11:02:13 AM ET
ALNY	Stock news	34,533 Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Curated Wealth Partners LLC	Defense World	Oct 18, 4:41:08 AM ET
ALNY	Stock news	Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results	GuruFocus	Oct 15, 9:00:00 AM ET
ALNY	Stock news	Alnylam vs. Ionis: Here's the Better Bad-News Buy	The Motley Fool	Oct 10, 4:44:00 AM ET
ALNY	Stock news	Alnylam Pharmaceuticals (NASDAQ:ALNY) and Onconetix (NASDAQ:ONCO) Critical Comparison	Defense World	Oct 10, 2:46:52 AM ET
ALNY	Legal	Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm	GlobeNewsWire	Oct 5, 11:00:00 AM ET
ALNY	Legal	Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation	GlobeNewsWire	Oct 5, 9:00:00 AM ET
ALNY	Legal	Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz	GlobeNewsWire	Oct 2, 5:40:00 PM ET
ALNY	Stock news	Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform	Seeking Alpha	Sep 28, 12:04:19 PM ET
ALNY	Stock news	4 RNA Therapeutics Stocks Leading the Next Wave of Innovation	Zacks Investment Research	Sep 28, 12:01:10 PM ET
ALNY	Stock news	18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.	The Motley Fool	Sep 28, 5:23:00 AM ET
ALNY	Stock news	Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook	Defense World	Sep 21, 5:03:22 AM ET
ALNY	Stock news	Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook	MarketBeat	Sep 20, 12:02:16 PM ET
ALNY	Stock news	Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial	MarketBeat	Sep 19, 9:02:29 PM ET
ALNY	Stock news	Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript	Seeking Alpha	Sep 17, 4:08:49 PM ET
ALNY	Stock news	Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture	The Motley Fool	Sep 15, 4:44:00 AM ET
ALNY	Stock news	Arizona State Retirement System Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY	Defense World	Sep 10, 3:09:34 AM ET
ALNY	Stock news	Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript	Seeking Alpha	Sep 8, 11:55:30 AM ET
ALNY	Press release	Alnylam to Webcast Presentations at Upcoming September Investor Conferences	Business Wire	Sep 2, 8:01:33 AM ET